Cost-utility analysis of eribulin versus capecitabine in HER-2 negative advanced or metastatic breast cancer in China

Abstract Objective: To evaluate the cost-utility of eribulin versus capecitabine in the treatment of HER-2 negative advanced or metastatic breast cancer(AMBC). Methods: Based on the data of a phase III trial, a partition survival modelwas constructed with a study duration of 10 years. Uncertainty analysis were used to evaluate the robustness of the results. Results: The results showed that compared with capecitabine group, the eribulin group obtained 0.24 more QALY, spent $5287.11 more, and ICUR was $22084.93/QALY, which was less than the threshold. uncertainty analysis showed that the results were robust, and the probability of eribulin being cost-utility is 69.28% at the threshold of $33881.17. Conclusions: Eribulin is cost-utility than capecitabine in the treatment of HER-2 negative AMBC.